Sep 30 |
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine
|
Sep 26 |
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
|
Sep 24 |
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal
|
Sep 23 |
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
|
Sep 23 |
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
|
Sep 23 |
Biohaven up 15% on troriluzole trial results for spinocerebellar ataxia
|
Sep 23 |
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)
|
Sep 20 |
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia
|
Aug 26 |
BofA starts Biohaven at buy, cites "fast-follower" approach
|
Aug 9 |
Biohaven Non-GAAP EPS of -$3.50 misses by $1.80
|